Dr. Gerald Krystal, Ph.D.
Co-Founder, Chairman of the Advisory Board, and Chief Scientific Advisor
Senior Scientist, Terry Fox Laboratory, BC Cancer Research Centre
Professor, Department of Pathology and Laboratory Medicine, University of British Columbia

Dr. Gerald Krystal is an internationally renowned scientist in the field of immune and hemopoietic cell signal transduction. In 1996, he discovered, molecularly cloned and patented SHIP1 (SH2-containing inositol 5'- phosphatase), a master regulator that controls the activity of immune cells. This protein is found only in hemopoietic cells and Dr. Krystal has since shown that SHIP1 regulates multiple signaling cascades involved in cell proliferation, survival and immune cell activation. Dr. Krystal is recognized as the world's foremost authority on SHIP1.

 

Dr. Susan M. MacDonald, M.D.
Professor and Associate Chair, Department of Medicine, Johns Hopkins University

Dr. Susan MacDonald is a Professor of Medicine and the first woman Associate Chair of the Department of Medicine at the Johns Hopkins University School of Medicine. She received her M.D. degree from the University of Massachusetts Medical School and did her Osler Internal Medicine Internship and Residency training at Johns Hopkins Hospital. She was a Postdoctoral Fellow in Clinical Rheumatology and in the Division of Allergy and Clinical Immunology. She joined the faculty in the Department of Medicine at Johns Hopkins as an Assistant Professor in 1987 and has remained at Hopkins ever since.

 

Dr. John C. Cambier, Ph.D.
Ida and Cecil Green Distinguished Professor and Chairman, Department of Immunology, University of Colorado Denver School of Medicine and National Jewish Health

Dr. John Cambier received Masters and Ph.D. training in virology and immunology at the University of Iowa and undertook postdoctoral training the University of Texas Southwestern Medical Center before being appointed to the faculty at Duke University in 1978. In 1983 he was recruited to the National Jewish Medical and Research Center in Denver, where he served as Head of the Division of Basic Sciences in the Department of Pediatrics. While working in this capacity he was also Director of Immunology at Cadus Pharmaceutical from1994 to1999. In 1999, Dr. Cambier became the first permanent chair of the Integrated Department of Immunology, which is a fusion of new academic departments at the University of Colorado School of Medicine and National Jewish Medical and Research Center.

 

Dr. William Kerr, Ph.D.
Professor, Microbiology and Immunology and Professor, Pediatrics, Upstate Medical University

Dr. William Kerr is an Empire Scholar of the State of New York and the Murphy Family Professor of Childrens' Oncology Research at Upstate Medical University in Syracuse. Dr. Kerr's research over the last decade has primarily focused on the role that SHIP1 plays in lymphoid biology, stem cell biology and allogeneic transplantation. Dr. Kerr has been continuously funded by the U.S. National Institutes of Health for over a decade.

 

Dr. Mark Coggeshall, Ph.D.
Robert S. Kerr, Jr. Endowed Chair in Cancer Research, Adjunct Professor, Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center

Dr. Mark Coggeshall received his Ph.D. from Duke University in Microbiology & Immunology and has done post-doctoral work at Washington University and Scripps Clinic. Working as a new assistant professor and in collaboration with Dr. Gerry Krystal, Dr. Coggeshall first identified SHIP1 as a mediator of inhibitory signal transduction in B cells as caused by the IgG receptor Fc(gamma)RIIb in B cells. He was granted a highly-competitive Scholar award from the Leukemia & Lymphoma society in 1998 and promoted to associate professor with tenure in 1998. Dr. Coggeshall was recruited to the Oklahoma Medical Research Foundation in 1999 and was awarded the Robert S. Kerr Foundation Chair in cancer research and made a full member of the Institute in 2002.

 

Dr. Susheela Tridandapani, Ph.D.
Associate Professor, Department of Internal Medicine, The Ohio State University

Dr. Susheela Tridandapani received her Ph.D. from the Ohio State University. She is currently a tenured Professor at the Ohio State University College of Medicine and serves as the Associate Director for Research in the Division of Pulmonary and Critical Care Medicine. She has spent the last 16 years investigating the role of SHIP1 in immune regulation. Dr. Tridandapani has published 65 papers related to phosphatase biology and serves on grant review panels for the NIH and the American Heart Association.